Mitogen-regulated proteins (also known as proliferin; mrp/plf) are nonclassical members of the PRL/GH family. They are expressed at high levels during midgestation when they are thought to induce angiogenesis and uterine growth. There are between four and six mrp/plf genes, and three different complementary DNAs have been cloned. Here we identify a fourth mrp/plf gene (mrp4) that we have cloned and characterized. MRP4 is 91% identical in amino acid sequence with the other MRP/PLF proteins but is missing two glycosylation sites that are present in the other forms. Consistent with the loss of two of three glycosylation sites, the expressed form of MRP4 has a lower apparent molecular weight compared with other MRP/ PLFs. In vivo, mrp4 is expressed in the placenta and the adult skin. Expression of mrp4 messenger RNA peaks in the placenta on day 12. In the skin, mrp4 expression is specific to the ears and tails of mice. Our results suggest that, as well as having growth and angiogenic effects during pregnancy, the MRP/PLFs may have functions in nonreproductive tissues. Unique among the members of the mrp/plf family for its expression in the hair follicles of the tail and ear, MRP4 is expected to have a singular role in the growth and development of these follicles.
has a lower apparent molecular weight compared with other MRP/ PLFs. In vivo, mrp4 is expressed in the placenta and the adult skin. Expression of mrp4 messenger RNA peaks in the placenta on day 12. In the skin, mrp4 expression is specific to the ears and tails of mice. Our results suggest that, as well as having growth and angiogenic effects during pregnancy, the MRP/PLFs may have functions in nonreproductive tissues. Unique among the members of the mrp/plf family for its expression in the hair follicles of the tail and ear, MRP4 is expected to have a singular role in the growth and development of these follicles. (Endocrinology 141: 1863-1871, 2000) P ROTEINS OF THE PRL/GH (PRL/GH) family play essential roles in growth and reproduction in mammals. Humans contain three placenta-specific variants of human (h) GH (1), whereas rodents have evolved numerous placental-expressed descendents of PRL (2) . In the mouse, the placental members of the family include placental lactogens I and II (mPLs) (3) (4) (5) , proliferin-related protein (PRP) (6) ; the more recently identified homologs of the rat PRL-like proteins (PLP A,B,C␣, Cv, E through L, and d/t-PRP) (7) (8) (9) (10) (11) (12) , and the mitogen-regulated proteins (proliferins; MRP/PLF) (13) . MRP/PLFs are glycoproteins consisting of a polypeptide core of 21 kDa and appear by gel electrophoresis to be of average sizes varying from 27K to 38K. Like some other members of the PRL/GH family, the MRP/PLFs are synthesized in the placenta, and their synthesis is temporally regulated during gestation (6, 14) . Expression of the mrp/plf genes in the placenta begins as early as E7, peaks at midgestation (E9 -11), then declines through the remainder of gestation. In situ hybridization and immunohistochemistry have identified the trophoblastic giant cells as the site of MRP/PLF synthesis in the placenta, from which it is released into both the maternal bloodstream and the amniotic fluid (15) . MRP/PLFs are believed to function during pregnancy as placental angiogenesis factors through their interaction with the mannose-6-phosphate receptor (16) and as uterine growth factors through another receptor that is specific for MRP/PLFs and does not recognize mannose-6-phosphate (17) . PLF1 also has been described as having an intracellular role, in preventing muscle differentiation (18, 19) .
The mouse genome contains between four and six mrp/plf genes (20) and previous to this report, three complementary DNAs (cDNAs) had been cloned: plf1 from serum-stimulated 3T3 cells (21) , plf2 from a Balb/c mouse placental cDNA library (22) , and mrp3 from a Swiss mouse embryo fibroblast library (23) . The three MRP/PLFs are approximately 98% identical in amino acid sequence and the variations in sequence do not disrupt any predicted structural motifs. Thus it is likely that all three previously identified MRP/PLFs have a similar structure. Each of the identified MRP/PLFs contain three N-glycosylation motifs within the sequence of the mature secreted protein, and all placental and 3T3 forms are glycosylated (13, 22, 24) . Because MRP/PLF binds at least two different receptors during gestation, only one of which recognizes mannose-6-phosphate, the level of glycosylation could be important in determining the functional interactions of the MRP/PLFs with their receptors in vivo (16, 17, 25) .
Here we describe a fourth mrp/plf messenger RNA (mRNA) (mrp4) that we have cloned, sequenced and characterized. The mature protein produced from this newly discovered member of the mrp/plf gene family is 91% identical in amino acid sequence to the other members of the family. MRP4 lacks two of the three glycosylation sites found on the other MRP/PLFs, and when expressed, it appears to contain less carbohydrate than the other MRP/PLFs. Expression of mrp4 mRNA is consistent with the presence of MRP/ PLF protein found in the placenta in the latter half of gestation and that has a lower apparent molecular weight than the plasma form of MRP/PLFs. MRP4 is also the only mrp/plf mRNA species detected in hair follicles of the tail and the ears of adult mice. These results suggest that, as well as functioning to stimulate uterine growth and placental vascularization during pregnancy, the MRP/PLFs also may have a specific function in adult hair follicles. Because mrp4 is the only member of the mrp/plf gene family expressed in the tail and the ear, this gene may play a singular role in these tissues.
Materials and Methods

Animals and Materials
CF-1 and FVB mice, originally obtained from Charles River Laboratories, Inc. (Wilmington, MA), were bred and cared for at the Laboratory Animal Facility at Iowa State University under a 12-h light, 12-h dark cycle. For pregnant animals, the day of the plug was counted as day 0. Animal care was provided by an animal caretaker and an attending veterinarian. This research was conducted in accordance with the standards set forth in the NIH guide for the care and use of laboratory animals. Animals were killed by cervical dislocation before removal of tissues for the described studies. Prior approval was obtained from the Iowa State University Committee on Animal Care for all procedures performed on the animals used in these studies.
Polyclonal anti-MRP rabbit sera and preimmune sera were prepared as described (26) . pRSV-plf1 and pRSV-plf2 plasmids and a set of cosmids containing mrp/plf-hybridizing sequences were gifts from Jiandie Lin and Daniel Linzer (Northwestern University). The pBluescript II KS (ϩ) plasmid (pBKSIIϩ) was obtained from Stratagene (La Jolla, CA), and the pcDNA3 expression vector was obtained from Invitrogen (Carlsbad, CA). The full mrp3 gene extending from Ϫ1450 to 600 bp past the poly A site (including introns) was obtained from David Denhardt (Rutgers University) in four separate pieces. The full-length genomic clone from Ϫ1450 was reconstructed almost completely except for an approximately 230 bp AccI-PvuII fragment of intron I and a 300 bp EcoRI fragment of intron 3, which were removed during cloning. The reconstructed gene was placed downstream of the CMV (cytomegalovirus) enhancer (obtained from pcDNA3) to produce pCMV-MRP3. Tunicamycin was from Sigma (St. Louis, MO). Dulbecco-Vogt's modified Eagles medium with high glucose (DMEG) was from Life Technologies, Inc. (Rockville, MD).
RNA isolation and RT-PCR
Immediately after their removal, tissues were frozen under liquid nitrogen and stored at Ϫ70 C until use. Frozen tissue was pulverized in liquid nitrogen using a mortar and pestle, and RNA was isolated using Tri-Reagent (Life Technologies, Inc.) according to the manufacturer's instructions. For RT, 250 ng of total RNA was incubated with or without 40 U of Superscript II reverse transcriptase (Life Technologies, Inc.) in 5-l reaction mixtures containing 75 mm KCl, 3 mm MgCl 2 , 10 mm DTT, 112 ng poly dT primers, 400 m each of the four dNTPs (dATP, dGTP, dCTP, dTTP), and 50 mm Tris⅐HCl (pH 8.3 at RT). The reaction mixtures were incubated at 42 C for 50 min, 50 C for 10 min, then 75 C for 15 min.
For PCR, the following primers were used; mrp/plf downstream exon I (DE1), 5Јtaagcctgggtaggactctgc3Ј (ϩ45 to ϩ65), or (DE1B) 5Јctctgca-gagatgctcccttc3Ј (ϩ59 to ϩ79) and mrp/plf upstream exon V (NUE5), 5Јcatgatatttcagaagcagagcac3Ј (ϩ778 to ϩ756). Briefly, 0.5 l of the RT reaction mix was added to a 25-l volume containing 1 U of Taq Polymerase, 20 pmoles of each primer, 200 m of each of the four dNTPs, 1.5 mm MgCl 2 , 50 mm KCl, and 10 mm Tris-HCl (pH 8.3). The thermal cycling conditions were as follows: 95 C for 2 min to denature, then 40 cycles at 95 C (30 sec), 66 C (1 min), and 72 C (1.5 min) with a final 3 min at 72 C. The PCR products were resolved by electrophoresis through a 1.5% agarose gel and examined by ethidium bromide staining.
Diagnostic restriction digestion to distinguish between the mrp/plf mRNAs
The diagnostic RT-PCR assay for the mrp/plfs is based on minor differences in the cDNA sequences of these closely related gene products that result in the presence or absence of restriction sites within the cDNA that can be used to distinguish between the mrp/plf mRNAs (Fig. 1) . For restriction digestion, one-fifth of the reaction mixture from the RT-PCR reaction was subjected to one additional round of PCR using DE1B and NUE5 primers and 62.5 m of each of the four dNTPs, 0.9 mm MgCl 2 and 1 Ci 32 P-␣dCTP in a 25-l volume. The sample was heated to 98 C for 4 min, 64 C for 1 min, then 72 C for 20 min. The radiolabeled cDNA was precipitated with 70% ethanol in the presence of 0.3 m sodium acetate with 10 g yeast transfer RNA as a carrier. Digestion was carried out using 1 U each of BsoFI (New England Biolabs, Inc., Beverly, MA) and BstXI at 55 C overnight, or 5 U of NdeI (Life Technologies, Inc.) at 37 C including 100 g/ml BSA (New England Biolabs, Inc.). The radiolabeled and digested products were resolved by electrophoresis through a 2% agarose gel or an 8% or 10% polyacrylamide gel. The gel was dried, and the amount of radioactivity associated with each band was determined using a phosphorimager and ImageQuant software (Molecular Dynamics, Inc., Sunnyvale, CA). Positive controls for identification of specific mrp/plf cDNAs were amplified from pRSV-plf1 or pRSV-plf2 cDNAs, or were produced using mRNA isolated from COS cells that had been transiently transfected with pCMV-MRP3. The diagnostic RT-PCR was validated using known mixes of mrp/plf cDNAs followed by amplification and diagnostic RT-PCR. The amount of each cDNA was then determined quantitatively after restriction digestion and found to reflect the expected ratio of each cDNA.
Other mrp/plf primers used for RT-PCR in these studies were DAP1 (Ϫ230 with the addition of ccac at the 5Ј end; 5Јccactagtcagag-catgaacat3Ј) and M3V55 (Ϫ129; with the addition of ccactag at the 5Ј end 5Јccactagtcatggtatctaggctactt3Ј).
Cloning and sequencing of the mrp4 cDNA
The mrp4 complementary DNA (cDNA) was cloned from day 13 CF-1 mouse placenta. Total placental RNA was isolated and reverse transcribed as described under RNA isolation and RT-PCR. The fragment was amplified by PCR using the following primers: DE1; 5Јtaagcctgggtag-gactctgc3Ј (ϩ45 to ϩ65), ZMRPUE5; 5Јgaaaagcttgtcaacaacaaattcaaaag3Ј (ϩ820 to ϩ801). Twenty-seven cycles of 95 C (30 sec), 64 C (1 min) and 72 C (1.5 min) were performed using a low error rate amplification kit (Expand High Fidelity PCR System, Roche Molecular Biochemicals, Indianapolis, IN). The PCR product was precipitated with ethanol, then digested 5Ј and 3Ј of the coding regions using PstI and HincII restriction endonucleases respectively. The resulting cDNA fragment was ligated into pBKSIIϩ that had been cut with these same restriction endonucleases. The plasmid pBKS-mrp4 was sequenced by the DNA Synthesis and Sequencing Facility at Iowa State University to verify the sequence of the mrp4 cDNA insert. Two of the clones were sequenced. Because the two sequences differed in sequence at five base positions, total mRNA isolated from two different tail samples were amplified by RT-PCR and the amplicons sequenced. The resulting sequences matched each other and clone 2 with the exception of a single base at position 221 in clone 2 which was A. The base in this position in the two amplified total tail RNA samples was G, which matched that of the other three cloned mrp/plfs. The base at position 221 was therefore taken to be G because the amplified tail mRNA sequences were the sum of sequences of many mRNAs in each sample whereas the cDNA clone 2 was the result of a single copy of one mRNA.
Expression of MRP4 in COS cells
The mrp4 cDNA was subcloned into pcDNA3 by digestion of pBKSmrp4 with SmaI and XhoI and insertion of the mrp4 cDNA into the blunt-ended HindIII and XhoI sites of pcDNA3 to make pcDNA3-mrp4. pcDNA3-Plf1 was made by cloning the HindIII/XbaI fragment of pRSVPlf 1 into the same sites in pcDNA3. COS cells were transiently transfected with pcDNA3-MRP4 or pcDNA3-PLF1 using DEAE-Dextran as coprecipitant (27) . After transfection, the cells were grown in DMEG 10% calf serum for 48 h, then switched to 2% calf serum with or without 5 g/ml tunicamycin for 24 h. The culture medium was collected and spun in a microcentrifuge for 1 min and then stored at 4 C. The cells were scraped into lysis buffer (0.5% NP40, 100 U/ml Trasylol, 10 Ϫ5 m PMSF, 20 mm HEPES, pH 7.25) and stored frozen at Ϫ70 C.
Western blot analysis
Tissue homogenates for Western blot analysis were prepared as follows: halves of two or more placentae from pregnant mice were collected on either day 11 or day 14 of gestation, pooled according to day of gestation and homogenized in the same lysis buffer used for cultured cells above. Large tissue debris were spun out, and the supernatants were saved. Transfected COS cell lysates or homogenates from day 11 or day 14 placentae were separated on a 15% polyacrylamide-SDS gel as described previously (28) . The proteins were electroblotted to nitrocellulose membranes (Nitrobind; Micron Separations, Inc., Westborough, MA), and the MRP/PLFs were detected using rabbit anti-MRP/PLF antiserum at a dilution of 1/200, followed by treatment with horseradish peroxidase-conjugated protein A (Sigma) and Western blotting detection reagents (Amersham International, Buckinghamshire, UK).
Immunohistocemistry
Tissues were fixed in 4% paraformaldehyde in PBS (0.14 m NaCl, 2.7 mm KCl, 4 mm Na 2 HPO 4 , 14.7 mm KH 2 PO 4 , pH 7.4) for 1-2 h at 4 C immediately after collection. Samples were then rinsed in PBS and stored in 70% ethanol until sectioned. For immunodetection of MRP, 6 m sections were rehydrated and stained as previously described (29) using a polyclonal rabbit anti-MRP/PLF serum (89rb13a) or a preimmune serum from the same animal, each at a dilution of 1/500. Primary antibody was detected using biotinylated goat antirabbit and horse radish peroxidase conjugated to avidin, and visualized by a peroxidase substrate, diamino benzidine tetrahydrochloride (ABC kit; Vectastain; Burlingame, CA). Samples were counter-stained with hematoxylin and eosin, dehydrated, and mounted with permount (Fisher Scientific, Pittsburgh, PA) with a coverslip on top.
Identification of the promoters for the different mrp/plf genes
Cosmid clones containing mrp/plf-hybridizing sequences and a reconstructed mrp3 gene from Ϫ1450 to ϩ600 bp past the poly A site and genomic DNA were amplified using primers that recognize the sequence from ϩ310 to ϩ335 (exon 3; 5Јacaaaagccccatgagatgcaatac3Ј) and from ϩ455 to ϩ435 (exon 4; 5Јactcactagatcgtccagagg3Ј). PCR-amplified fragments were digested with EcoRI for 4 h at 37 C and then digested with either BsoFI or BstXI as described for diagnostic RT-PCR. The fragments were resolved through a 2% agarose gel. Individual clones that produced diagnostic PCR digestion patterns consistent with a particular mrp/plf cDNA were sequenced across the promoter region using a primer ϩ71 to ϩ43 (UE1; 5Јcatctctgcagagtcctacccaggcttag3Ј) that hybridizes with the 5Ј end of mrp4 and the three mrp/plfs identified previous to this report (21) (22) (23) .
Results
A new mrp/plf mRNA that is expressed in the midgestational placenta
Because the placenta was previously the only tissue in which mrp/plf expression was observed, we used the diag- nostic RT-PCR protocol diagrammed in Fig. 1 to determine the relative proportions of mrp/plf mRNAs expressed in the placenta. By incorporating 32 P␣CTP into the final round of amplification, we were able to quantitatively determine, using a phosphorimager, the amount of each restriction fragment. The major form of mrp/plf expressed during gestation was mrp3. This can be seen visually in Fig. 1 in which the majority of the radioactivity is associated with the 289-and 246-bp fragments that are diagnostic for mrp3. Less radioactivity was associated with the 318-bp fragment that is diagnostic for plf1, and no radioactivity was associated with the 275-bp fragment diagnostic for plf2. However, we also found a form of mrp/plf mRNA that was not digested at the internal BsoF1 and BstXI sites present in the three cloned mrp/plfs. The undigested form of mrp/plf was found in the placenta at lower levels before day 11 and peaked between days 12 and 14 ( Fig.  1) (14) . These results suggested the presence of a fourth, previously unidentified, mrp/plf mRNA that is expressed in the placenta during late gestation that does not contain the internal BsoFI or BstXI sites present in the three previously cloned mrp/plfs.
Cloning of mrp4
The fourth mrp/plf cDNA that was identified as uncut by the diagnostic RT-PCR procedure was cloned from day 13 placental RNA and sequenced as described in Materials and Methods to reveal a previously unknown mrp/plf cDNA (mrp4) with 91% amino acid identity to plf1 (Fig. 2) . Two noteworthy differences between mrp4 and the other three mrp/plfs are changes in amino acids 77 (Ser to Pro) and 88 (Asp to His) that would disrupt two of the three putative N-glycosylation sites found on the other three MRP/PLF mature protein sequences.
Other possibly significant alterations include a stretch of five amino acids from 103 to 107 in which there are four differences between MRP4 and PLF1. Also, there is an inframe deletion of two amino acids 167 and 168. Secondary structure analysis by NNPREDICT query (30) predicts that the substitutions in MRP4 at positions 186 and 188 result in the loss of helical tendency in the four ␣ carbons between 185 and 188.
Mrp4 expression in the placenta
Among the nucleotide sequence differences between the mrp/plfs is the presence of a NdeI site at ϩ649 that is unique to mrp4. To obtain further evidence that the mrp4 gene accounts for the uncut portion of cDNA observed during later gestation, rather than a different mrp/plf that also lacks the BsofI/BstxI sites, diagnostic RT-PCR was carried out on placental RNAs using NdeI in place of BsofI and BstxI. Measured in this way, mrp4 is found at higher relative levels on days 13-15 than days 9 -11 of gestation as was shown previously with the BsofI/BstxI cleavage ( Fig. 1) (14) . Thus, both diagnostic RT-PCR methods identify the same gene product, mrp4, as having a different expression pattern relative to plf1 and mrp3.
Measurements of the relative amounts of plf1, mrp3, and mrp4 in the placenta as a function of gestation showed that the proportion of mrp3 varied between about 50% and 75% of the total mrp/plf mRNA throughout gestation. The relative amounts of plf1 and mrp4 varied reciprocally (Fig. 3) . The maximum proportion of mrp4 was reached on day 12 when it constituted about 40% of the mrp/plf mRNA in the placenta. At this time, the proportion of plf1 is at its lowest of about 13% from a high of about 35% on day 7 of gestation.
MRP4 is glycosylated differently from PLF1
To determine how the loss of two potential N-glycosylation sites affects the glycosylation of MRP4, COS cells were transiently transfected with pcDNA3-MRP4 or pcDNA3-PLF1. Culture media and lysates of the transfected cells were analyzed by Western blot and compared with the MRP/PLFs found in placental homogenates (Fig. 4) . As expected, PLF1 migrated with an apparent molecular weight ranging between 32K and 36K (13) . By comparison, placental minces secrete MRP/PLFs of 27 kDa and 38 kDa. The 38-kDa MRP/ PLF band was previously identified as containing MRP3 and PLF1 (14) . MRP4 migrated at the same rate as the 27-kDa placental MRP/PLF. The 27-kDa MRP/PLF has a time course of appearance in gestation similar to that of the mrp4 mRNA.
PLF1 and MRP4 are polypeptides having the same apparent molecular weight. This is demonstrated by a comparison of the nonglycosylated forms of the two proteins (Fig. 4) . The nonglycosylated forms of the MRP/PLFs, produced by transfected cells that were incubated with tunicamycin, migrated as expected for the 21K molecular weight proteins predicted from their cDNA sequences. These results demonstrate that the difference in electrophoretic migration rates between the two MRP/PLFs is due to their glycosylation. Thus, the loss of two glycosylation sites in the MRP4 sequence results in the addition of less carbohydrate to this protein compared with PLF1. The placental MRP with the same apparent size as the recombinant MRP4 produced by COS cells is more predominant in day 14 placental lysates than day 11 lysates. This is consistent with the delayed expression of MRP4 mRNA relative to PLF1 and MRP3 in the placenta (Fig. 3) (14) .
Differential cell and tissue-specific expression of mrp/plf genes
Although mrp/plfs were initially demonstrated by Northern blot analysis to be expressed only in the placenta (6), we show here that the mrp/plfs are differentially expressed in a variety of mouse tissues (Fig. 5) . Mrp/plf mRNAs were detected in the small intestine and tail but not in the liver, lungs, backskin, adult ribs, or large intestine. The same expression pattern was found in males and females. Mrp/plfs were detected in some, but not all, stomach samples and at low levels in some samples of backskin (data not shown). Mrp/plfs were also detected in 3T3 cells as expected from previous studies (13) . The major mrp/plf expressed by 3T3 cells is plf1 consistent with the cloning of this mrp/plf from these cells (21) . Samples incubated without reverse transcriptase showed no visible bands (Fig. 5A ). Restriction analysis of radiolabeled cDNAs showed that the mouse tail produces only mrp4, whereas the small intestine and 3T3 cells produce mostly plf1 with lower levels of mrp3 (Fig. 5B) . Mrp4 seems to be expressed at lower relative levels in the small intestine but is absent from 3T3 cells. The PCR product from cDNA reverse transcribed from whole tail RNA was sequenced, and the results confirmed that the mrp/plf sequence of the mRNA expressed in the tail is the same as that of the mrp4 cDNA cloned from day 13.5 placentae.
The mouse tail skin and the mouse ear skin express unique keratins that are different from those found in normal backskin. Therefore, RNA from the ear also was subjected to diagnostic RT-PCR and compared with the results from tailskin RNA (Fig. 5B) . Although mrp/plf cDNA was not detected in most normal backskin samples (Fig. 5A) , mrp/plf cDNAs were regularly identified in both the ears and tailskin where mrp4 was the only identified mrp/plf (Fig. 5B) . Mrp4 also was the major mrp/plf species detected in the remainder of the tail after the skin was removed (data not shown).
Identification of the mrp4 promoter
To identify the mrp4 promoter, a series of cosmid clones containing mrp/plf sequences were screened for the presence of the mrp4 gene by several PCR-based assays. First, diagnostic PCR was performed between exons 3 and 4 on isolated cosmid clones containing mrp/plf hybridizing genes to identify specific mrp/plf-containing cosmids. Individual clones were identified that produced the predicted restriction digestion pattern for each of the mrp/plfs. Clear restriction patterns were obtained for five cosmid clones; two cosmids gave patterns specific for plf1 (cos4 and cos5), two gave mrp3-specific patterns (cos2 and cos3) and one gave the mrp4 restriction pattern (cos6). Clones that produced PCR products with mrp/plf-specific digestion patterns were also sequenced across the promoter region after PCR amplification starting with a primer in the common 5ЈUTR. By this method, the promoter known as plf42 was shown to be contiguous with the gene encoding plf1, the promoter plf149 corresponded to mrp4 and the mrp3 promoter corresponded to mrp3.
To confirm the promoter cDNA contiguities deduced from the cosmid clones, RT-PCR was performed using 5Ј primers that would amplify transcripts initiating at upstream promoters located between 140 or 230 bp of the normal transcriptional start site (data not shown). When performed on RNA from the tail (using primers DAP1 and NUE5), the promoter for mrp4 was confirmed to be plf149. Similarly for 3T3 cells, which express predominantly plf1, RT-PCR using M3V55 and UE5 produced upstream transcripts that corresponded to the plf42 promoter. As expected, the placental mrp3 cDNA was found to be linked to the mrp3 promoter when RT-PCR was performed using DAP1 and NUE5.
Localization of MRP4 in the hair follicles of the mouse tail
To determine the location of the MRP4 protein in the adult tail, immunohistochemistry was performed using a rabbit polyclonal anti-MRP/PLF serum. Binding of anti-MRP/PLF antibody was detected in the hair follicles of the tail skin (Fig.  6) . The location of MRP/PLF in the hair follicles appeared to be limited to the keratinocytes that make up the outer root sheath. Preimmune sera did not stain these structures.
FIG. 3. Placental expression of the mrp/plfs. A, upper panel:
Quantitation by diagnostic RT-PCR of the proportional expression of plf1, mrp3, and mrp4 by the placenta through gestation. These data were also used, along with the total amount of RNA determined by Northern blot analysis, to determine the relative amounts of each of the mrp/plf genes in gestation (13) . The results shown are the average of four separate experiments in which different placental samples were analyzed. The values were averaged to obtain the results shown. As a result of different combinations of samples in each experiment, the values are the average of two (days 8,10,12,13) or four (days 9,11,15) separate values. Shown are the sample standard deviations. A, Lower panel: The expression of mrp4 was analyzed during gestation using the restriction endonuclease NdeI, which digests mrp4, but not the other identified mrp/plfs. Shown are averages of two experiments. B, Digestion pattern of the mrp/plf amplicons with NdeI.
Discussion
The MRP/PLFs exhibit several very important biological activities. They stimulate proliferation and angiogenesis and inhibit differentiation. However, until this report, they have only been demonstrated to be expressed in the placenta. There are between four and six mrp/plf genes in the mouse (20) and three of the cDNAs have been previously identified. Here, we describe the identification and cloning of a fourth mrp/plf (mrp4) that is transiently expressed during gestation in a manner distinct from the other mrp/plfs and which is uniquely expressed in the tail and ear of adult mice.
MRP4 is more different in sequence from the other three MRP/PLFs than are the other three MRP/PLFs from each other. Whereas MRP4 is 91% identical with PLF1, the other three MRP/PLFs (PLF1, PLF2 and MRP3) are 99% identical with each other. The MRP4 protein also is differently glycosylated because two differences in the amino acid sequence result in the loss of two potential N-glycosylation sites from MRP4 compared with the other MRP/PLFs. This difference in glycosylation might alter the stability of the protein, its interaction with receptors or its ability to move from one tissue to another. For example, we have demonstrated that the 27-kDa form of MRP/PLF in the placenta that we identified as MRP4 is not found in the bloodstream or the amniotic fluid of the pregnant mouse as are other MRP/PLFs (14) .
Mrp4 expression peaks on day 12 of gestation. This is at a time during which expression of the other two mrp/plfs is decreasing (6, 14, 31) . Interestingly, it is the same time at which proliferin-related protein (PRP) peaks (32) . PRP is closely related in sequence to the mrp/plfs with 37% identity to PLF1 in amino acid sequence and 95% identity to PLF1 in the first 97 nucleotides (6) . PRP opposes the effect of bFGF on angiogenesis, and the delayed increase in PRP expression in the placenta is proposed to effect a rapid inhibition of the angiogenic effects of the MRP/PLFs (16) . Similar to MRP4, PRP is not found in the amniotic fluid, but unlike MRP4, PRP is found in maternal serum (32) .
Individual members of the mrp/plf family are differentially regulated in vivo in both tissue-specific and temporal patterns. As well as being expressed in the placenta, the mrp/plfs are expressed in the small intestine, tail, and ear and sometimes were observed in the stomach. Although not detected in most samples of backskin, occasionally samples showed low levels of mrp/plf expression. This expression is mainly of mrp3 (Fassett, J. T., and M. Nilsen-Hamilton, manuscript in preparation). The mrp/plfs were not detected in the liver, lungs, ribs, and large intestines. Different mrp/plf genes are expressed in different tissues. Plf1 is the major form of mrp/plf mRNA expressed in the stomach, small intestine and 3T3 cells, while mrp3 is the major form expressed by the midgestational placenta. Mrp4 is the only form of mrp/plf expressed in the ear and tail skin. As we have shown a broader tissue expression pattern of the mrp/plfs beyond the placenta, which is their site of highest expression, so are other genes of the PRL/GH family found to be expressed in high levels in one primary tissue and secondarily in other tissues. Beyond its primary site of expression in the pituitary, PRL, the evolutionary precursor to the rodent utero/placental gene family, also is expressed in other tissues, including the dermis (33) . The placental lactogens I and II are expressed in the testes in addition to their high levels of expression in the placenta (34) .
By immunohistochemistry, the MRP4 protein is localized in the keratinocytes of the outer root sheath of the hair follicle in the tail. These cells may not be the site of the protein's initial synthesis, but they are apparently the site of highest accumulation of MRP4. Thus, it is likely that the keratinocytes are either the source of MRP4 or the site of its action or perhaps both. The observation that the mrp/plfs are expressed in a tissuespecific manner suggests that these genes are regulated by distinct factors. As well, the site of expression of MRP4 is specific to the location in the body, e.g. tail vs. back. This observation parallels those of the keratin gene family where the keratin pair of 48 kDa and 65 kDa is expressed specifically in suprabasal cells of the tail epidermis, in the filiform papillae of the tongue, and at low levels in suprabulbar cells of newborn hair follicles (35) . In mice, a 70-kDa keratin (mk2e) is expressed specifically in the ear, tail, and footsole epidermis (36) . The ear and tail are also the specific sites of mrp4 gene expression.
Here we have shown that the promoter for mrp4 is the previously cloned plf149 promoter and the plf42 promoter is the sequence upstream of the plf1 coding sequence (37) . Although 98% homologous to the promoter for plf1 (plf42), the mrp4 (plf149) promoter is not stimulated by the addition of serum (37) or bFGF (38) . Interestingly, there are a number of differences between the plf149 and mrp3 and plf42 promoters that affect recognizable regulatory elements. One of these changes affects the FGF response element (FRE) present in mrp3, which is disrupted in the other two promoters (38) . This and other alterations in regulatory sequences are likely to be responsible for the differential expression of the mrp/plfs in mouse tissues.
In summary, we have identified a fourth mrp/plf gene with a distinct tissue expression pattern from the other mrp/plf genes. Despite the high identity in nucleotide sequence, it is striking that a large number of the differences in nucleotide sequence of the first 550 bp of these promoters result in alterations of recognizable regulatory element sequences. These observations suggest that the mrp/plf family may have evolved to take advantage of specific combinations of transcriptional regulatory elements for the regulation of mrp/plf gene expression in particular cell types or under special physiological conditions. The resulting MRP/PLF proteins, which are also 91% to 98% identical in amino acid sequence, may not differ in their function. However, there may be other differences. For example, the difference in glycosylation of MRP4 compared with MRP3 and PLF1 could result in altered stability or tissue access for MRP4, or MRP4 may interact with a different set of receptors. Thus, we suggest that MRP4 may function as a growth factor and/or angiogenesis factor in the vicinity of the hair follicle in the tail and ear as MRP3 and PLF1 are proposed to do in the placenta.
